B Novocure b (NVCR) missed quarterly sales expectations Thursday as total U.S. patients actively using its cancer treatment declined sequentially for the first time ever - prompting NVCR stock to topple. NVCR Stock Slides On Tough Quarter There's a lot of moving parts for NVCR stock right now. [Extracted from the article]
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.